In the present study, we first reported that mutation in Atrx sensitizes lung cancer to both anti-PD1 and anti-CTLA4, which indicates that Atrx may act as a biomarker of immune therapy and facilitate patient stratification. The gene discussed is CTLA4; the disease is lung cancer.